Bayer Says Eliapixant Phase 2b Cough Trial Was Successful

Montag, 06.09.2021 08:41 von PLX

• (PLX AI) – Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough.
• • Results from PAGANINI Phase IIb dose-finding study presented at the virtual European Respiratory Society (ERS) International Congress 2021
• • Currently no treatment approved for refractory chronic cough, a condition affecting one to five percent of people worldwide
• • The primary efficacy outcome was met showing a statistically significant reduction in the 24-hour cough count (average hourly cough frequency based on 24-hour sound recordings) of up to 27% for eliapixant 75 mg twice daily over placebo after 12 weeks of treatment
• • These results will guide us to advance our clinical development strategy of eliapixant, company says